- Home
- KRRO
KRRO
Korro Bio Inc.
as 05-09-2025 4:00pm EST
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 209.6M | IPO Year: | 2019 |
| Target Price: | $90.67 | AVG Volume (30 days): | 102.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.13 - $98.00 | Next Earning Date: | 05-07-2025 |
| Revenue: | $4,821,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -61.5% | Revenue Growth (next year): | 55.56% |
Latest Korro Bio Inc. News
KRRO Breaking Stock News: Dive into KRRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
a month ago
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Simply Wall St.
2 months ago
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth?
GlobeNewswire
2 months ago
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
2 months ago
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
GlobeNewswire
2 months ago
Korro to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
4 months ago
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update
GlobeNewswire
4 months ago
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Compare KRRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRRO Korro Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.